Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3569
Peer-review started: July 23, 2019
First decision: July 31, 2019
Revised: September 1, 2019
Accepted: September 11, 2019
Article in press: September 11, 2019
Published online: November 6, 2019
Processing time: 108 Days and 13.2 Hours
Portopulmonary hypertension (PoPH) is not uncommon in patients waiting for liver transplantation (LT). Severe PoPH has a very high perioperative mortality rate and is still considered a contraindication for LT. Many patients with liver disease require but cannot receive LT due to severe PoPH and eventually died. We report a patient with severe PoPH who underwent successful LT and had near normal pulmonary pressure without drug treatment.
A 39-year-old woman was hospitalized with the chief complaint of jaundice and exertional dyspnea and fatigue. Caroli disease and liver cirrhosis was diagnosed 6 years previously. Her liver disease met the criteria for LT. However, right heart catheterization showed that her mean pulmonary artery pressure was increased at 50 mmHg, pulmonary vascular resistance was 460 dyn∙s/cm5 and pulmonary artery wedge pressure was 20 mmHg, which may have been the reasons for her chief complaint. The patient was diagnosed with severe PoPH and was not listed for LT immediately. After 5 mo of pharmacotherapy, her severe PoPH was moderate, and she underwent successful LT. Pulmonary artery pressure steadily decreased according to post-operative echocardiographic monitoring and drugs have been discontinued for a month.
The safety of LT can be greatly improved by reducing mean pulmonary artery pressure to a low level, and LT may cure PoPH.
Core tip: Peri-operative pharmacotherapy was administered to a patient with portopulmonary hypertension (PoPH) to reduce pulmonary pressure in order to ensure the safety of liver transplantation (LT). LT may eventually cure severe PoPH.